Slide 1: AusBioInvest 2022 Presentation
- @ Dimerix él (ASX:DXB) ~~ AusBiolnvest 2022 Presentation QoY Perth, October 2022 Authorised for lodgment by the Board of the Company
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 3: About Dimerix
About Dimerix Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease Lead Drugiiaagidate Om cial Ready Strong Pipeline DMX-200 Demonstra
Slide 4: Share price and shareholders
For personal use only Share price Shareholders *includes R&D Incentive Refund $6m received post quarter end
Slide 5: Development pipeline
Development pipeline Program Indication Preclinical Phase 1 Phase 2 Phase 3 Key milestones Phase 2 demonstrated promising efficacy and safety’, next study planned Diabetic Kidney Disease F s—isSCiS@Y with support form Australian Centre for Diabetes Innovation; anticipated H1234+ DMX-200 ------------
Slide 6: For personal use only
2,500.00 For personal use only REG 1x P3 Ren Reg 1x P3 Ren 2,000.00 WW 1x P1 Ren WW 1x P2 Mul 1,500.00 CTRY 1x P3 Ren CTRY 1x P2 Ren 1,000.00 WW 1x P3 Ren Reg 1x Pre Ren 500.00 Reg 1x Pre Ren WW 1x P1 Ren 0.00 Jan-20 Apr-20 Aug-20 Nov-20 Feb-21 Jun-21 Sep-21 Dec-21
Slide 7: Phase 3 studies investigating FSGS treatments
Phase 3 studies investigating FSGS treatments No therapies yet approved specifically for FSGS Drug candidate Primary interim (accelerated approval) endpoint ACTIONS3' DMX-200 CCR2 inhibitor Placebo Percent change in uPCR and eGFR slope at week 35 Dual Proportion of patients achieving uPCR < 1.5g/g a
Slide 8: Focal Segmental Glomerulosclerosis
| Focal Segmental Glomerulosclerosis A healthy kidney has little to no protein in the urine Focal =some Inside a healthy kidney Inside a damaged kidney Segmental = sections blood blood Glomerulo = of the kidney filtering units filter me Sclerosis = are scarred urine cy one \ = | A ) . = _ ' ° = Prot
Slide 9: Key mechanisms that cause sclerotic kidney disease
3 key mechanisms that cause sclerotic kidney disease ATIR — blocked by angiotensin receptor blocker (ARB) CCR2 —CCR2 is the receptor for MCP-1; DMX-200 inhibits CCR2 to block attraction of inflammatory cells » into the kidneys? 1 Hyperfiltration of and hypertension within blood vessels of the glomer
Slide 10: DMX-200 - working on inflammatory signalling pathway
DMX-200 — working on inflammatory signalling pathway A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) Small molecule Clear Development Path [Easy and convenient dosing Extensive regulatory engagement New Chemical Entity
Slide 11: DMX-200: Phase 2 met primary and secondary endpoints
DMX-200: Phase 2 met primary and secondary endpoints Average reduction in proteinuria after 16 weeks treatment on DMX-200 versus placebo compared to standard of care alone in FSGS patients! 0.0% — ee *86% of patients demonstrated YO iY reduced proteinuria on DMX-200 “No safety conceins ~ reduced 80%
Slide 12: ACTIONS - FSGS Phase 3 study design
O ACTIONS - FSGS phase 3 study design FSGS CLINICAL STUDY Global study recruiting across “70 sites: A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes Australia/NZ: 9 sites Asia: 9 sites Europe: 18 sites Latin America: 11 sites UK: 6 sites USA: 20 sites IMerlx of DM
Slide 13: ACTIONS Study part recruitment status
Oo ACTIONS Study part 1 recruitment status FSGS CLINICAL STUDY Patients recruited*: * Ontrack to complete Part 1 recruitment Estimated and dosing Q4 2022 90% * Part 1 data outcome anticipated mid-2023 80% 100% 70% 50% 40% 30% 20% | f Northern hemisphere summer holiday «| _ + Start up activities 0% .
Slide 14: Dimerix
Dimerix A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. Advancing three Phase 3 opportunities Lead program to report mid 2023 Dimerix HQ 425 Smith St, Fitz